[Newsmp] In the first half, the average sales of listed pharmaceutical and bio companies exceeded KRW 100 billion. (Closing accounts are in December, separate financial statements)
According to Korean data provider FnGuide, a total of 148 pharmaceutical manufacturers posted about KRW 15.3333 trillion in sales in the first half.
The average sales per company was KRW 103.6 billion, exceeding KRW 100 billion, but only 28 out of 148 companies posted above average sales.
Thirty companies, including 28 companies that exceeded the average, saw their half-year sales surpass KRW 100 billion, but the other 30 companies fell short of KRW 10 billion.
The combined sales of 30 companies with sales of more than KRW 100 billion amounted to about KRW 11.18 trillion, accounting for 72.9% of the total sales of pharmaceutical manufacturers.
Among them, 10 pharmaceutical and bio companies posted more than KRW 400 billion in sales, the top 7%, and their combined sales were KRW 6.6083 trillion, or 43.1% of the total sales.
By company, Celltrion had the largest sales with KRW 1.366 trillion, followed by Samsung Biologics with KRW 1.15 trillion.
In terms of consolidated financial statements, Samsung BioLogics' sales amounted to KRW 1.1627 trillion, slightly exceeding Celltrion's KRW 1.1467 trillion, but Celltrion was slightly ahead in separate financial statements.
Followed by the leaders, Yuhan Corporation exceeded KRW 500 billion with KRW 865.7 billion, Chong Kun Dang Pharmaceutical with KRW 702.8 billion, GC Pharma with KRW 586.9 billion, and Daewoong Pharmaceutical KRW 565.9 billion.
Seegene achieved more than KRW 400 billion in sales with KRW 497.2 billion, Hanmi Pharmaceutical with KRW 464.6 billion, Humasis KRW 442.7 billion, and HK inno.N KRW 431 billion.
Moreover, Kwang Dong Pharmaceutical, Jeil Pharmaceutical, Boryung Pharmaceutical, Il Dong Pharmaceutical, JW Pharmaceutical, and Dong-A ST recorded the KRW 300 billion mark, and DongKook Pharmaceutical, Kolmar BNH, Handok, SK Bioscience, Huons, and Daewon Pharmaceutical were in the KRW 200 billion range.
Celltrion Pharmaceutical, Dongwha Pharm, Samjin Pharmaceutical, Korea United Pharm., Hugel, Youngjin Pharmaceutical, Hana Pharm, and Il-Yang Pharmaceutical also exceeded KRW 100 billion.
